Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
DCF Valuation
Base-case fair value
kr 67.06
Intrinsic kr 89.41 · 25% MOS
Base-case summary
Our base-case DCF for Vitrolife AB (VITR.XSTO) projects 10 years of free cash flow growth at 8.9% for years 1–5 and 4.5% for years 6–10, anchored to 8.9% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from kr 491M in trailing free cash flow, this produces an intrinsic value of kr 89.41 per share. A 25% safety margin gives a fair value of kr 67.06.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
kr 491M
Cash & equivalents
kr 809M
Total debt
kr 1.6B
Shares outstanding
135M